Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 27, 2026

CZR Exchange Launches CZR DEX, Expanding Into High-Performance On-Chain Trading

View original at globenewswire.com
CZR Exchange Launches CZR DEX, Expanding Into High-Performance On-Chain Trading George Town, Cayman Islands, March 27, 2026 (GLOBE NEWSWIRE) -- CZR DEX CZR Exchange, a global cryptocurrency trading platform offering spot and derivatives markets, today announced the launch of CZR DEX (czrdex.com), a decentralized tradin…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The platform is engineered to deliver faster execution speeds, real-time trading functionality, and a simplified, intuitive user experience, while maintaining the core principle of self-custody

    60% confidence

  • CZR DEX has been developed to address key limitations historically associated with decentralized trading environments, including latency, fragmented liquidity, and complex user interfaces

    60% confidence

  • The future of trading is not purely centralized or decentralized, but a convergence of both designed to deliver efficiency, flexibility, and control at scale

    60% confidence

  • The objective is to bring performance and usability to on-chain trading, where users should not have to compromise between control and execution quality

    60% confidence

  • CZR DEX has been developed with scalability as a core priority, with infrastructure designed to support increasing trading volumes, improved responsiveness, and ongoing feature expansion

    60% confidence

  • The company plans to continue enhancing the platform through iterative development, focusing on performance optimization, user experience improvements, and expanded functionality

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com